IGF2BP2 levels can also use as a prognostic indicator of acute myelocytic leukemia 25, breast cancer 53, endometrial adenocarcinoma 54, liposarcoma 55, pancreatic cancer 27, hepatocellular carcinoma 30 and OSCC 35. This evidence concerns the gene IGF2BP2 and familial pancreatic carcinoma.